Aurinia Pharmaceuticals Inc. AUPH
16.21 USD -0.09 (-0.55%)
At closeNov 11, 2026, 4:24 PM EST
16.10 -0.11 -0.70%
After hours · Nov 11, 4:24 PM ET
15.75 Day range 16.36
13.95 52-week range 18.62
- YTD
- +1.63%
- 1 year
- +3.38%
News
benzinga.com Why Is Teva Stock Trading Lower on Monday? Teva halts its Phase 2 TOPAS-MSA study after an interim futility analysis showed low odds of meeting the primary efficacy endpoint.
benzinga.com RBC Capital Maintains Sector Perform on Aurinia Pharmaceuticals, Raises Price Target to $18 RBC Capital analyst Douglas Miehm maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Sector Perform and raises the price target from $16 to $18.
zacks.com Aurinia Pharmaceuticals (AUPH) Tops Q3 Earnings Estimates Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.2 per share. This compares to earnings of $0.23 per share a year ago.
benzinga.com Aurinia Pharmaceuticals Raises FY2026 Sales Guidance from $315.000M-$325.000M to $325.000M-$330.000M vs $330.261M Est Aurinia Pharmaceuticals (NASDAQ:AUPH) raises FY2026 sales outlook from $315.000 million-$325.000 million to $325.000 million-$330.000 million vs $330.261 million estimate.- benzinga.com Aurinia Pharmaceuticals Q3 EPS $0.23 Beats $0.22 Estimate, Sales $83.699M Beat $83.691M Estimate Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.22 by 4.55 percent. This is unchanged from the same period last…
businesswire.com Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and nine months ended September 30, 2026 and provided an update on…
zacks.com Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to Decline Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com Why Aurinia Pharmaceuticals (AUPH) is a Top Growth Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zacks.com Why Aurinia Pharmaceuticals (AUPH) is a Top Momentum Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.- benzinga.com TD Cowen Maintains Buy on Aurinia Pharmaceuticals, Raises Price Target to $18 TD Cowen analyst Stacy Ku maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy and raises the price target from $17 to $18.
defenseworld.net Critical Review: Aurinia Pharmaceuticals (NASDAQ:AUPH) versus Madrigal Pharmaceuticals (NASDAQ:MDGL) Aurinia Pharmaceuticals (NASDAQ: AUPH - Get Free Report) and Madrigal Pharmaceuticals (NASDAQ: MDGL - Get Free Report) are both healthcare companies, but which is the superior investment? We will…
zacks.com Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises AUPH settles voclosporin patent litigation with Teva, delaying potential generic competition in the United States until December 2036.
benzinga.com Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are up during Thursday's premarket session as the company has entered into a settlement agreement with Teva Pharmaceutical Industries Ltd. (NYSE:TEVA).
benzinga.com Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug Aurinia Pharmaceuticals shares rise after settling patent litigation with Teva, which can launch generic voclosporin no earlier than December 2036.- benzinga.com Aurinia Settles Teva Patent Litigation, Protecting Voclosporin Exclusivity In U.S. Until December 2036 And Affirming Validity Of Key Patents Through 2037 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, "Aurinia") have entered into a settlement agreement with Teva…
businesswire.com Aurinia Settles Patent Litigation with Teva EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Settles Patent Litigation with Teva.
seekingalpha.com Aurinia Pharmaceuticals Doubles Down On Its Pipeline Aurinia Pharmaceuticals is running the phase 4 PRESERVE trial in lupus nephritis, which tests combinations containing the company's drug Lupkynis. Lupkynis could face potential challenges to its…
benzinga.com RBC Capital Maintains Sector Perform on Aurinia Pharmaceuticals, Raises Price Target to $16 RBC Capital analyst Douglas Miehm maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Sector Perform and raises the price target from $15 to $16.
zacks.com Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.16 per share a year ago.
benzinga.com Aurinia Pharmaceuticals Affirms FY2026 Sales Guidance of $315.000M-$325.000M vs $323.065M Est Aurinia Pharmaceuticals (NASDAQ:AUPH) affirms FY2026 sales outlook from $315.000 million-$325.000 million to $315.000 million-$325.000 million vs $323.065 million estimate.
benzinga.com Aurinia Pharmaceuticals Q2 EPS $0.28 Beats $0.24 Estimate, Sales $83.220M Beat $79.357M Estimate Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.24 by 16.67 percent. This is a 75 percent increase over earnings…
businesswire.com Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress.
seekingalpha.com Playing The Biotech Breakout With Insiders Biotech stocks are consolidating after a breakout, with bullish insider Wall Street sentiment. AbCellera Biologics and Alpha Cognition stand out for insider buying, revenue growth, and high Seeking…
gurufocus.com Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced the initiation of PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNISÂ
businesswire.com Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced the initiation of PRESERVE, a Phase 4, multicenter study investigating the combination…
zacks.com Aurinia (AUPH) Upgraded to Strong Buy: Here's Why Aurinia (AUPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
zacks.com Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
zacks.com 5 Small Drug Stocks to Invest in Amid a Biotech Comeback Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
zacks.com Aurinia (AUPH) Moves 6.5% Higher: Will This Strength Last? Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in…
fool.com Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million 814,606 common shares acquired for a total transaction value of approximately $12.5 million, based on a weighted average price of $15.29 per share. The purchase represents 6.66% of Kevin Tang's total…
benzinga.com 10 Health Care Stocks Whale Activity In Today's Session 
benzinga.com Aurinia Pharmaceuticals' New Analysis Of Aurora 1 Phase 3 Study Of Lupkynis For Lupus Nephritis Shows Statistically Significant 53% Reduction In The Risk Of Renal-related Event Or Death Hazard ratios (HRs) favored treatment with LUPKYNIS for the following individual components of the composite endpoint: death (HR=0.19 [an 81% reduction in risk]; p=0.0929), treatment failure (HR=0.45…- benzinga.com Tang Capital Raises Aurinia Pharmaceuticals Holding to 10% Tang Capital Management, LLC announces that on June 2, 2026, it acquired 206,005 common shares (the "Common Shares") of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (the "Issuer") at a price of US…
benzinga.com Aurinia Pharmaceuticals Affirms FY2026 Sales Guidance of $315.000M-$325.000M vs $326.190M Est Aurinia Pharmaceuticals (NASDAQ:AUPH) affirms FY2026 sales outlook from $315.000 million-$325.000 million to $315.000 million-$325.000 million vs $326.190 million estimate.
benzinga.com Aurinia Pharmaceuticals Q1 EPS $0.25 Beats $0.19 Estimate, Sales $77.705M Beat $77.390M Estimate Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $0.19 by 31.58 percent. This is a 56.25 percent increase over…- benzinga.com Aurinia Pharmaceuticals Signs Agreement To Acquire Kezar Life Sciences For $6.955/Share In Cash Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs, announced today it…
benzinga.com Why Aurinia Pharmaceuticals Stock Is Surging Monday Morning Aurinia Pharmaceuticals shares are trading higher Monday after announcing a leadership transition seen as a sign of continuity and strategy.
benzinga.com Aurinia Pharmaceuticals (AUPH) Stock Drops After Strong Quarter, Softer Forward Revenue Targets Aurinia Pharmaceuticals shares are trading lower Thursday afternoon after the lupus-focused drugmaker posts a blowout fourth quarter and raises expectations for continued growth in 2026.
benzinga.com Earnings Breakdown: Aurinia Pharmaceuticals Q4 
benzinga.com Earnings Scheduled For February 26, 2026 
benzinga.com Earnings Summary: Aurinia Pharmaceuticals Q4 
benzinga.com Aurinia Pharmaceuticals Sees FY2026 Sales $315.000M-$325.000M vs $326.858M Est Aurinia Pharmaceuticals (NASDAQ:AUPH) sees FY2026 sales of $315.000 million-$325.000 million vs $326.858 million analyst estimate.- benzinga.com Aurinia Pharmaceuticals Q4 EPS $1.53, Sales $77.114M Beat $74.845M Estimate Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $1.53 per share which beat the analyst consensus estimate of $0.21 by 618.31 percent. This is a 15200 percent increase over…
benzinga.com Earnings Preview: Aurinia Pharmaceuticals 
benzinga.com Earnings Scheduled For November 4, 2025 - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers SciSparc (NASDAQ: SPRC) shares increased by 28.2% to $5.68 during Monday's after-market session. The company's market cap stands at $2.2 million.
- benzinga.com Earnings Scheduled For July 31, 2025
benzinga.com US Stocks Likely To Open On A Mixed Note: 'Nothing Good Happens Above A 5% Yield,' Says Expert U.S. stock futures were fluctuating on Friday after a mixed close on Thursday. Futures of benchmark indices were mixed in premarket.- benzinga.com Earnings Scheduled For May 12, 2025
- benzinga.com Earnings Scheduled For February 27, 2025